A Study to Observe the Treatment Patterns and Outcomes of Patients in Japan With Kidney Cancer That is Unable to be Removed by Surgery or That Has Spread
NCT03161145 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 297
Last updated 2017-10-03
Summary
A medical review chart study in Japan to describe the treatment patterns and outcomes of patients with kidney cancer that is unable to be removed by surgery or that has spread. The clinical data is to be abstracted using electronic data capture (eDC) from patient medical records in Japan.
Conditions
Sponsors & Collaborators
-
Ono Pharmaceutical Co. Ltd
collaborator INDUSTRY - lead INDUSTRY
Principal Investigators
-
Bristol-Myers Squibb · Bristol-Myers Squibb
Eligibility
- Min Age
- 20 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2016-12-09
- Primary Completion
- 2017-08-31
- Completion
- 2017-08-31
Countries
- Japan
Study Locations
More Related Trials
-
A Study to Observe the Onset of Immune-related Adverse Reactions in Patients With Non-surgical or Renal Cell Carcinoma (RCC) That Has Spread
NCT03663946 ·Status: COMPLETED
-
Study Of AG-013736 (Axitinib) As Second-Line Treatment In Patients With Metastatic Renal Cell Cancer (mRCC)
NCT00569946 ·Status: COMPLETED ·Phase: PHASE2
-
Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214)
NCT02231749 ·Status: COMPLETED ·Phase: PHASE3
-
Retrospective Study on the Safety of Nivolumab in Patients With mRCC and Renal Failure
NCT07117409 ·Status: TERMINATED
-
BMS-936558 (MDX-1106) In Subjects With Advanced/Metastatic Clear-Cell Renal Cell Carcinoma (RCC)
NCT01354431 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of the Effectiveness of Cabozantinib in Combination With Nivolumab as First-line Treatment of Advanced Renal Cell Carcinoma (aRCC) in Adults
NCT05361434 ·Status: ACTIVE_NOT_RECRUITING
-
Metabolomic Profiling in Renal Cell Carcinoma
NCT02001493 ·Status: UNKNOWN
-
Anlotinib Plus Everolimus as First-line Treatment for Advanced Non Clear Cell Renal Cell Carcinoma
NCT05124431 ·Status: UNKNOWN ·Phase: PHASE2
-
Master Protocol to Study Treatment Patterns, Medication Adherence, Health and Economic Outcomes and Unmet Needs in RCC
NCT04375150 ·Status: COMPLETED
-
A Study to Learn About the First and Later Lines of Medicines in Treating People With Metastatic Renal Cell Carcinoma (mRCC).
NCT05858749 ·Status: COMPLETED
-
Study of IMO-2055 in Metastatic or Locally Recurrent Clear Cell Renal Carcinoma
NCT00729053 ·Status: COMPLETED ·Phase: PHASE2
-
Study Of AG-013736 In Patients With Refractory Metastatic Renal Cell Cancer
NCT00282048 ·Status: COMPLETED ·Phase: PHASE2
-
Real World Study of Effectiveness of Sunitinib or Sorafenib to Chinese Unresectable Locally Advanced or Metastatic PRCC
NCT07024680 ·Status: RECRUITING
-
Palliative Radiofrequency Ablation in Metastatic Renal Cell Carcinoma Patients
NCT00891475 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Acarbose in Combination With Standard Therapy in Metastatic Renal Cell Carcinoma (RCC)
NCT05487859 ·Status: WITHDRAWN ·Phase: PHASE2
-
Nivolumab in Patients With Metastatic Renal Cell Carcinoma Who Have Progresses During or After Prior Systemic Anti-angiogenic Regimen
NCT03013335 ·Status: COMPLETED ·Phase: PHASE2
-
Fluzoparib in Patients With Metastatic Non-clear Cell Renal Cell Carcinoma
NCT04535687 ·Status: COMPLETED ·Phase: PHASE2
-
Functional Imaging in the Assessment of mRCC Response to Sunitinib
NCT01977586 ·Status: WITHDRAWN ·Phase: NA
-
Targeted Therapy With or Without Nephrectomy in Metastatic Renal Cell Carcinoma: Liquid Biopsy for Biomarkers Discovery
NCT02535351 ·Status: TERMINATED ·Phase: PHASE3
-
Nivolumab in Treating Patients With Localized Kidney Cancer Undergoing Nephrectomy
NCT03055013 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
A Pivotal Study Of SU011248 In The Treatment Of Patients With Cytokine-Refractory Metastatic Renal Cell Carcinoma.
NCT00077974 ·Status: COMPLETED ·Phase: PHASE2
-
A Research Study for Patients With Metastatic Renal Cell Carcinoma
NCT00106613 ·Status: COMPLETED ·Phase: PHASE2
-
Study of CP-461 in Patients With Advanced Renal Cell Cancer
NCT00036036 ·Status: COMPLETED ·Phase: PHASE2
-
Anti-angiogenesis Agent AG-013736 in Patients With Metastatic Renal Cell Carcinoma
NCT00076011 ·Status: COMPLETED ·Phase: PHASE2
-
IMP321 Phase 1 Trial in Metastatic Renal Cell Carcinoma (MRCC)
NCT00351949 ·Status: COMPLETED ·Phase: PHASE1